Tideglusib
Chemical compound
From Wikipedia, the free encyclopedia
Tideglusib (NP-12, NP031112) is a potent and irreversible[1] small molecule glycogen synthase kinase 3 (GSK-3) inhibitor.[2]
| |
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEBI | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C19H14N2O2S |
| Molar mass | 334.39 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Clinical trials
Tideglusib has been evaluated in clinical trials for:
- Alzheimer's disease and progressive supranuclear palsy. Both clinical trials were discontinued in 2011 (PSP) and 2012 (Alzheimer's disease) due to lack of efficacy[3][4][5][6][1]
- Congenital/juvenile-onset myotonic muscular dystrophy type I.[7]
Research
Tideglusib is or has been under investigation for multiple applications:
- Tooth repair mechanisms that promotes dentine reinforcement of a sponge structure until the sponge biodegrades, leaving a solid dentine structure. In 2016, the results of animal studies were reported in which 0.14 mm holes in mouse teeth were permanently filled.[8][9]
- Preclinical in vitro studies were carried out for neuroblastoma and ovarian cancer with significant ROS-induced apoptosis.[10][11]
- Arrhythmogenic right ventricular cardiomyopathy as of 2025.[12]